Devalingam Mahalingam

15PUBLICATIONS
112CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 15, 2026
KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

|Apr 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.

Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Feb 06, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

|Jan 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

|Aug 28, 2025
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.

Imran Nizamuddin, Tarik Demir, Katrina Dobinda

Pageof 3

Frequent Collaborators

3 joint publications

Samuel J Klempner

3 joint publications

Benedito A Carneiro

2 joint publications

Pamela N Munster

2 joint publications

Byoung Yong Shim